Your browser doesn't support javascript.
The Barts Health NHS Trust COVID-19 cohort: characteristics, outcomes and risk scoring of patients in East London.
Crocker-Buque, T; Williams, S; Brentnall, A R; Gabe, R; Duffy, S; Prowle, J R; Orkin, C; Kunst, H; Cutino-Moguel, T; Zenner, D; Bloom, B; Melzer, M; de Freitas, S; Darmalingam, M; McCafferty, K; Kapil, V; Pfeffer, P; Martin, J; Gourtsoyannis, Y; Chandran, S; Dhariwal, A; Rachman, R; Milligan, I; Mabayoje, D; Adobah, E; Falconer, J; Nugent, H; Yaqoob, M; Collier, D; Pearse, R; Caulfield, M; Tiberi, S.
  • Crocker-Buque T; The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK.
  • Williams S; The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK.
  • Brentnall AR; Wolfson Institute of Preventive Medicine, Queen Mary University of London, Mile End Road, London, UK.
  • Gabe R; Wolfson Institute of Preventive Medicine, Queen Mary University of London, Mile End Road, London, UK, Barts Clinical Trials Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, Mile End Road, London, UK.
  • Duffy S; Wolfson Institute of Preventive Medicine, Queen Mary University of London, Mile End Road, London, UK.
  • Prowle JR; The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK, The William Harvey Research Institute, Queen Mary University of London Charterhouse Square, London, UK.
  • Orkin C; The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK.
  • Kunst H; The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK.
  • Cutino-Moguel T; The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK.
  • Zenner D; Centre for Global Public Health, Queen Mary University of London, Mile End Road, London, UK.
  • Bloom B; The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK.
  • Melzer M; The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK, Whipps Cross University Hospital, Barts Health NHS Trust, Leytonstone, London, UK.
  • de Freitas S; The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK.
  • Darmalingam M; Whipps Cross University Hospital, Barts Health NHS Trust, Leytonstone, London, UK.
  • McCafferty K; The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK.
  • Kapil V; The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK, The William Harvey Research Institute, Queen Mary University of London Charterhouse Square, London, UK, St Bartholomew´s Hospital, Barts Health NHS Trust, West Smithfield, London, UK.
  • Pfeffer P; The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK, The William Harvey Research Institute, Queen Mary University of London Charterhouse Square, London, UK.
  • Martin J; Newham University Hospital, Barts Health NHS Trust, London, UK.
  • Gourtsoyannis Y; The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK.
  • Chandran S; The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK.
  • Dhariwal A; The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK.
  • Rachman R; The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK.
  • Milligan I; The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK.
  • Mabayoje D; The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK.
  • Adobah E; The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK.
  • Falconer J; The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK.
  • Nugent H; The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK.
  • Yaqoob M; The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK.
  • Collier D; Barts Clinical Trials Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, Mile End Road, London, UK, The William Harvey Research Institute, Queen Mary University of London Charterhouse Square, London, UK.
  • Pearse R; The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK, The William Harvey Research Institute, Queen Mary University of London Charterhouse Square, London, UK.
  • Caulfield M; The William Harvey Research Institute, Queen Mary University of London Charterhouse Square, London, UK.
  • Tiberi S; The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK, Newham University Hospital, Barts Health NHS Trust, London, UK.
Int J Tuberc Lung Dis ; 25(5): 358-366, 2021 05 01.
Article in English | MEDLINE | ID: covidwho-1225922
ABSTRACT

BACKGROUND:

Barts Health National Health Service Trust (BHNHST) serves a diverse population of 2.5 million people in London, UK. We undertook a health services assessment of factors used to evaluate the risk of severe acute respiratory coronavirus 2 (SARS-CoV-2) infection.

METHODS:

Patients with confirmed polymerase chain reaction (PCR) test results admitted between 1 March and 1 August 2020 were included, alongwith clinician-diagnosed suspected cases. Prognostic factors from the 4C Mortality score and 4C Deterioration scores were extracted from electronic health records and logistic regression was used to quantify the strength of association with 28-day mortality and clinical deterioration using national death registry linkage.

RESULTS:

Of 2783 patients, 1621 had a confirmed diagnosis, of whom 61% were male and 54% were from Black and Minority Ethnic groups; 26% died within 28 days of admission. Mortality was strongly associated with older age. The 4C mortality score had good stratification of risk with a calibration slope of 1.14 (95% CI 1.01-1.27). It may have under-estimated mortality risk in those with a high respiratory rate or requiring oxygen.

CONCLUSION:

Patients in this diverse patient cohort had similar mortality associated with prognostic factors to the 4C score derivation sample, but survival might be poorer in those with respiratory failure.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: State Medicine / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Aged / Female / Humans / Male Country/Region as subject: Europa Language: English Journal: Int J Tuberc Lung Dis Year: 2021 Document Type: Article Affiliation country: Ijtld.20.0926

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: State Medicine / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Aged / Female / Humans / Male Country/Region as subject: Europa Language: English Journal: Int J Tuberc Lung Dis Year: 2021 Document Type: Article Affiliation country: Ijtld.20.0926